Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical has expanded its long-standing partnership with University of Chicago Medicine to include the commercial deployment of its CT:VQ lung imaging solution, adding an initial package of prepaid scans to accelerate clinical use at one of the United States’ leading centres for complex lung disease. The move makes UChicago the fifth top-tier U.S. academic medical centre to adopt CT:VQ within five months of FDA clearance, a cluster of reference sites that the company says validates its commercialisation strategy, deepens its influence with key opinion leaders, and builds momentum to position CT:VQ as a new standard in pulmonary imaging alongside its broader hospital and industry partnerships.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company focused on respiratory imaging, using patented XV Technology to turn standard lung scans into detailed functional insights that help clinicians detect, diagnose and monitor lung disease earlier and more precisely. Its software portfolio, including FDA-cleared XV Lung Ventilation Analysis Software, CT LVAS and CT:VQ, is delivered via a SaaS model that integrates into existing hospital systems, and has been strengthened by AI capabilities gained through the 2023 acquisition of Imbio.
Average Trading Volume: 5,374,064
Technical Sentiment Signal: Buy
Current Market Cap: A$2.21B
For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.